Angiogenesis, the development and formation of new blood vessels, is important in a variety of physiological processes, such as growth and differentiation, ovulation, wound healing and neoplasia (Folkman and Klagsbrun, 1987; Folkman and Shing, 1992) . Increased vascular density has been shown to correlate with a higher incidence of metastases and a worse prognosis in breast cancer (Weidner et al., 1991; Toi et al., 1993) , lung cancer (Macchiarini et al., 1992; Yamazaki et al., 1994) , melanoma (Srivastava et al., 1988) , and in tumours of the prostate (Weidner et al., 1993) . Vascular proliferation is a requirement for solid tumour growth and is induced by angiogenic factors produced by the tumour or non-malignant cells. However, the mechanisms underlying angiogenesis in tumours are incompletely understood. Various growth factors have been shown to stimulate angiogenesis, including fibroblast factors, transforming growth factor (TGF)-oc, platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) . The relative importance of the individual angiogenic factors in most tumour types is still largely unclear.
Recent results with basic fibroblast growth factor (bFGF) in melanoma (Becker et al., 1989) , embryonal rhabdomyosarcoma (Schweigerer et al., 1987) and ovarian carcinoma (Crickard et al., 1994) (Carr and Mountain, 1977) .
Determination of VEGF expression Staining for VEGF protein was performed using a commercially available polyclonal anti-VEGF antibody (Ab-2; Dianova, Hamburg, Germany), generated by immunising rabbits with a peptide from the N-terminal region of VEGF165, and using a previously established method (Volm et al., 1991 Statistical analysis To determine whether there was a significant difference between PCNA labelling index or microvessel density in VEGF-positive tumours vs VEGF-negative tumours, the Wilcoxon rank sum test was used. In addition, to examine the relationship between VEGF expression and PCNA labelling index, the Jonckheere test was used which tests the equality of the medians against the ordered alternatives (Hollander and Wolfe, 1973) . The relationship of PCNA labelling index and microvessel density was assessed statistically by using linear regression analysis.
Results VEGF expression and tumour cell proliferation Ninety-one epidermoid lung carcinomas were analysed by immunohistochemistry with antibodies to vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA). Positive staining for VEGF was obtained in 54 out of 91 cases (59%). The expression of VEGF was mainly identified in the cytoplasma of tumour cells. In Figure  1 a two nests with predominantly cytoplasmatic immuno reactivity are shown. A weak positive VEGF staining was also seen on endothelial cells. Proliferating tumour cells were easily identified by nuclear immunostaining with the PCNA antibody (Figure lb) Figure   2 ).
VEGF expression and microvessel density The mean microvessel count in a 250 x field for all tumours was 9.4 + 10.1 (median, 6; range, 0-64). The areas of high vascularisation occurred most frequently at the margins of the carcinomas. An example of microvessel staining with factor VIII is shown in Figure Ic . The microvessel count (mean + s.d.) in VEGF-positive tumours was significantly higher than that in VEGF-negative tumours (10.9 + 11.2 vs 5.7 + 3.9; Wilcoxon rank sum test, P<0.05; Table I ).
Tumour cell proliferation and microvessel density Tumour cell proliferation, as assessed by the PCNA labelling index in the maximally immunostained areas, was correlated with tumour vessel density, measured in the vascular hotspots. There was no association between tumour cell PCNA labelling index and tumour vascularity (r = 0.07, P=0.48) (Figure 3 ). Sporn and Roberts (1985) proposed the term 'autocrine secretion' which is the ability of cells to produce and to respond to their own growth factors. The close relationship between VEGF expression and tumour cell proliferation in this study suggests that possibly VEGF could act similarly to bFGF or in a synergistic manner with bFGF (Goto et al., 1993) as an autocrine growth factor in human lung tumours. Four VEGF isoforms (VEGF121, VEGF165, VEGF189 and VEGF206) have been described in humans. VEGF165 is the most abundant isoform (Ferrara et al., 1992) . However, the significance of the various VEGF isoforms is unknown. Perhaps the different VEGF isoforms have different affinities to their receptors or may mediate distinct functions. The binding of VEGF to its receptors is dependent on cell surface-associated heparin-like molecules (Gitay-Goren et al., 1992) . The enhancing effect of heparin facilitates the detection of VEGF receptors on cell types that were not known previously to express such receptors (Gitay- Goren et al., 1992) .
To investigate whether VEGF is involved in lung tumour angiogenesis, the data of VEGF expression were correlated with vessel density. We found that the expression of VEGF was closely associated with the increment of vessel density. These data clearly support the role of VEGF as a mitogenic growth factor for vascular endothelial cells also in lung carcinomas. However, it is clear that the vascular phenotype in any tumour will be the result of a large number of factors influencing angiogenesis, but our correlation suggests that VEGF is at least one of the important factors governing angiogenesis in lung carcinomas.
The mitogenic activity of VEGF seemed to be restricted to vascular endothelial cells (Conolly et al., 1989; Senger et al., 1993) , and initial characterisation of VEGF receptors was therefore carried out using these cells. In the meantime, however, VEGF receptors were also detected on non-vascular endothelial cells such as HeLa cells, NIH3T3 cells (Gitay- Goren et al., 1992) , on several cell lines of human melanomas (Gitay-Goren et al., 1993) , and recently on ovarian carcinoma cells (Boocock et al., 1995) , but the function of the VEGF receptors in these cells is still unclear. Whether the receptors known so far mediate the proliferation enhancing effects of VEGF and whether they represent the only receptors for this family of factors remains to be established.
Because the growth of solid tumours needs an adequate vascular network for supply of oxygen and nutrients and in order to remove waste products, the vascular density and its influence on tumour cell proliferation was analysed in human epidermoid lung carcinomas. Although it has been established that tumour cell proliferation decreases with increasing distances from the blood vessels (Tannock, 1968) intratumoral endothelial cell proliferation. In contrast, Vermeulen et al. (1995) found an association between tumour cell labelling index, measured in the maximally Ki-67 immunostained areas, and tumour vascularity, measured in the vascular hotspots in colorectal adenocarcinomas, when a complete cross-section of the tumour was scanned. Taken together, the data suggest that growth factors controlling tumour growth are not the same as those involved in endothelial cell growth and that tumour cell proliferation and microvessel growth and/or density may be regulated by different mechanisms (Vartanian and Weidner, 1994) . Angiogenesis is a complex process that involves endothelial cell migration, capillary budding, neovascular remodelling, in addition to endothelial cell proliferation. The lack of correlation between microvessel density and tumour cell proliferation in our study and in the studies of others (Fox et al., 1993; Vartanian and Weidner, 1994; Porschen et al., 1994) supports this concept.
In conclusion, the close correlation of VEGF expression with tumour cell proliferation and angiogenesis in epidermoid lung carcinomas suggests that VEGF may act similarly to bFGFs as both a direct autocrine growth factor for their own tumour growth and as an indirect mediator of growth by stimulating tumour angiogenesis. Furthermore, the lack of correlation between tumour cell proliferation and intratumoral microvessel density indicates that tumour cell proliferation and microvessel growth and/or density may be regulated by separate mechanisms.
